Gordon Research Conferences
Meeting Details
Search:
  GO

Antibody Biology & Engineering
Gordon Research Conference

Connecting Antibody Biology, Structure and Function to Future Applications

Dates

March 20-25, 2016

Location

Hotel Galvez
Galveston, TX

Organizers

Chairs:
Richard Blumberg & Janine Schuurman

Vice Chair:
Mark Hogarth

Meeting Description

Antibodies are multi-faceted proteins that are capable of an array of important functions. They have a major part to play in immune protection against invading pathogens, play critical roles in a large variety of clinically important inflammatory and auto-immune diseases, play a central role in the induction of protection during vaccination and the knowledge from this is increasingly used in the clinic to generate highly effective therapeutic reagents. Antibodies in fact represent the largest class of biologic agents that are currently either in development or approved by the Food and Drug administration for the treatment of an enormous range of diseases.

The 2016 Gordon Research Conference on Antibody Biology and Engineering, which is the fourth in this series, will present in-depth coverage of recent advances in this exciting field, in an informal setting designed for maximal interaction. The conference will bring together academic researchers with their colleagues in the biopharma industry: it will provide an ideal opportunity for leading researchers from around the world to present and discuss cutting-edge data including unpublished findings.

The conference will mingle basic scientific aspects of antibodies like Antibody Structure and Dynamics, Generation of Antibody Diversity, Antibody Effector Mechanisms, Pathogenic and Protective Antibodies with applications of this knowledge to clinical development, focusing on the antibody as a therapeutic agent, including topics such as Bispecifics, Antibody-Drug Conjugates and other Novel Therapeutic Concepts to Modify Disease.

For the second time the conference will incorporate a Gordon Research Seminar as a specific means to foster involvement by scientists at the graduate student and post doctoral level. Planned by and for trainees, it will provide an opportunity for our junior researchers to present seminars and posters in a supportive, interactive environment.

Related Meeting

This GRC was held in conjunction with the "Antibody Biology & Engineering" Gordon Research Seminar (GRS). Refer to the associated GRS program page for more information.

Contributors

Final Meeting Program

Sunday
4:00 pm - 8:00 pmArrival and Check-in
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pmKeynote Session: Perspectives on Antibody Biology and Engineering
Discussion Leaders: Omid Vafa (TENEObio, Inc., USA) and Derry Roopenian (The Jackson Laboratory, USA)
7:40 pm - 7:50 pmOpening Remarks
7:50 pm - 8:30 pmSally Ward (Texas A&M University, USA)
"Targeting FcRn for Diagnosis and Therapy"
8:30 pm - 8:40 pmDiscussion
8:40 pm - 9:20 pmPaul Carter (Genentech, Inc., USA)
"The Rise of Bispecific Antibodies as Therapeutics"
9:20 pm - 9:30 pmDiscussion
Monday
7:30 am - 8:30 amBreakfast
8:30 amGroup Photo
9:00 am - 12:30 pmAntibody Structure and Dynamics in Relation to Function
This session focuses on new insights into how antibody structure influences its function and considers issues of evolutionary strategies, structural basis for antibody functions and how they can be manipulated.
Discussion Leaders: Brian Sutton (King's College London, United Kingdom) and John Desjarlais (Xencor, USA)
9:00 am - 9:25 amSarel Fleishman (Weizmann Institute of Science, Israel)
"Computational Design of Function, Stability and Conformational Change in Antibodies"
9:25 am - 9:35 amDiscussion
9:35 am - 10:00 amGary Gilliland (Janssen, USA)
"Structural Diversity in a Human Antibody Germline Library"
10:00 am - 10:10 amDiscussion
10:10 am - 10:40 amCoffee Break
10:40 am - 11:05 amFloyd Romesberg (The Scripps Research Institute, USA)
"Evolution of Immunological Molecular Recognition"
11:05 am - 11:15 amDiscussion
11:15 am - 11:40 amClarissa Jakob (AbbVie, USA)
"The Dynamic DVD-IgTM: Molecules in Motion at Atomic Resolution"
11:40 am - 11:50 amDiscussion
11:50 am - 12:00 pmTein Foong Leong (University of Dundee, United Kingdom)
"Engineering Novel IgG Antibodies to Probe Immunoglobulin Function and Develop Cancer Vaccines"
12:00 pm - 12:05 pmDiscussion
12:05 pm - 12:15 pmJohn Karanicolas (University of Kansas, USA)
"Modulating Antibody Activity Using Chemical Biology"
12:15 pm - 12:20 pmDiscussion
12:20 pm - 12:30 pmGeneral Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:30 pm - 9:30 pmModeling Antibody Diversity – Its Generation and Uses
This session focuses on understanding how diversity develops during an immune response and how this can be used for therapeutic approaches including novel mimetics, which target the antigen-antibody binding site.
Discussion Leader: George Georgiou (The University of Texas at Austin, USA)
7:30 pm - 7:55 pmJamie Scott (Simon Fraser University, Canada)
"Evolution of the Antibody Response During Hyper-Immunization with a Nanoparticle Vaccine Carrier"
7:55 pm - 8:05 pmDiscussion
8:05 pm - 8:30 pmJarrett Adams (University of Toronto, Canada)
"Synthetic Repertoires"
8:30 pm - 8:40 pmDiscussion
8:40 pm - 9:05 pmDeKuan Chang (AbVitro Inc, USA)
"AbPair: High Throughput Single Cell Sequencing of Tumor-Infiltrating Paired Immune Repertoires"
9:05 pm - 9:15 pmDiscussion
9:15 pm - 9:25 pmJeffrey Gildersleeve (National Cancer Institute, NIH, USA)
"Immunological Evolution of Antibodies in the Ganglioside GD2"
9:25 pm - 9:30 pmDiscussion
Tuesday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmThe Functionality of Antibodies and the Receptors Through Which They Operate: Functional Consequences
This session aims not to solely focus on Fc-gamma receptors/FcRn and IgG, but also on what other isotypes and recently identified receptors (e.g. TRIM21, FcRL) teach to explore new avenues of antibody uses and applications.
Discussion Leaders: Paul Parren (Genmab B.V., The Netherlands) and Falk Nimmerjahn (University of Erlangen-Nuremberg, Germany)
9:00 am - 9:25 amPeter Sun (National Institute of Allergy and Infectious Diseases, NIH, USA)
"Pentraxins, IgA and FcαRI"
9:25 am - 9:35 amDiscussion
9:35 am - 10:00 amLeo James (Medical Research Council, United Kingdom)
"Intracellular Neutralization and Innate Immune Activation by the Cytosolic Antibody Receptor TRIM21"
10:00 am - 10:10 amDiscussion
10:10 am - 10:40 amCoffee Break
10:40 am - 11:05 amBrian Sutton (King's College London, United Kingdom)
"The Dynamics of IgE and Its Receptor Interactions"
11:05 am - 11:15 amDiscussion
11:15 am - 11:25 amAnja Lux (University of Erlangen-Nurnberg, Germany)
"Impact of IgG Glycosylation on the Inflammatory Activity of IgG"
11:25 am - 11:30 amDiscussion
11:30 am - 11:40 amKristi Baker (University of Alberta, Canada)
"FcRn and Polymorphic FCGR2A Variants Co-Operatively Drive Immune-Complex Mediated Diseases"
11:40 am - 11:45 amDiscussion
11:45 am - 11:55 amFrank Beurskens (Genmab, The Netherlands)
"Functional Aspects of Antigen- and Fc-Dependent IgG Hexamer Formation"
11:55 am - 12:00 pmDiscussion
12:00 pm - 12:10 pmJan Terje Andersen (Oslo University Hospital / University of Oslo, Norway)
"Human IgG3 Is a Superior Mediator of Intracellular Anti-Viral Immunity"
12:10 pm - 12:15 pmDiscussion
12:15 pm - 12:30 pmGeneral Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
3:00 pm - 4:00 pmPower Hour
The GRC Power Hour is an optional informal gathering open to all meeting participants. It is designed to help address the challenges women face in science and support the professional growth of women in our communities by providing an open forum for discussion and mentoring.
Organizers: Erica Ollmann Saphire (The Scripps Research Institute, USA) and Jeanette Leusen (University Medical Center Utrecht, The Netherlands)
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:30 pm - 9:30 pmThe Functionality of Antibodies and the Receptors Through Which They Operate: Translation to Therapeutic Applications
This session aims not to solely focus on Fc-gamma receptors/FcRn and IgG, but also on what other isotypes and recently identified receptors (e.g. TRIM21, FcRL) teach to explore new avenues of antibody uses and applications.
Discussion Leaders: Paul Parren (Genmab B.V., The Netherlands) and Falk Nimmerjahn (University of Erlangen-Nuremberg, Germany)
7:30 pm - 7:55 pmJonathan Davis (Bristol-Myers Squibb, USA)
"Symmetric and Asymmetric Synergy Join to Drive Potency in a Novel Biologic HIV-1 Entry Inhibitor"
7:55 pm - 8:05 pmDiscussion
8:05 pm - 8:30 pmDavid Szymkowski (Xencor, Inc., USA)
"Engineering Fc Affinity for FcgammaRIIb to Generate Therapeutic Antibodies with Novel Mechanisms of Action"
8:30 pm - 8:40 pmDiscussion
8:40 pm - 9:05 pmJames Ernst (Genentech, USA)
"A Novel Tissue Specific Agonist of the FGF21 Pathway for the Treatment of Type II Diabetis"
9:05 pm - 9:15 pmDiscussion
9:15 pm - 9:25 pmGestur Vidarsson (Sanquin Research, The Netherlands)
"Immune Modulation Through Glycan-Coding of IgG: Biochemical Decryption of IgG-Responses Found Against Red Blood Cells and Platelets"
9:25 pm - 9:30 pmDiscussion
Wednesday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmDevelopment and Mechanisms of Pathogenic or Protective Antibodies
This session aims to focus on mechanisms and generation of pathogenic or protective antibodies and to explore features of antibodies involved in disease or protection beyond antigen specificity such as glycosylation or isotype and subclass.
Discussion Leader: Antonio Lanzavecchia (Institute for Research and Biomedicine, Università della Svizzera Italiana, Switzerland)
9:00 am - 9:25 amAntonio Lanzavecchia (Institute for Research and Biomedicine, Università della Svizzera Italiana, Switzerland)
"A New Mechanism of Antibody Diversification"
9:25 am - 9:35 amDiscussion
9:35 am - 10:00 amErica Ollmann Saphire (The Scripps Research Institute, USA)
"Antibodies Against Ebola Virus: Results of the Viral Hemorrhagic Fever Immunotherapeutic Consortium"
10:00 am - 10:10 amDiscussion
10:10 am - 10:40 amCoffee Break
10:40 am - 11:05 amLouis Weiner (Georgetown University, USA)
"Functional Genomic Screening to Identify Tumor-Based Molecular Determinants of Anti-Cancer Immune Responses"
11:05 am - 11:15 amDiscussion
11:15 am - 11:25 amWilliam Faison (Luxembourg Institute of Health, Luxembourg)
"Anchored Lineage Reconstruction Reveals B Cell Repertoire Convergence on Measles Virus Hemagglutinin Protein in Three Independent Vaccination Cohorts"
11:25 am - 11:30 amDiscussion
11:30 am - 11:40 amAlex Sevy (Vanderbilt University, USA)
"Generating Broadly Neutralizing Antibodies via Computational Design"
11:40 am - 11:45 amDiscussion
11:45 am - 11:55 amAmandeep Sangha (Vanderbilt University, USA)
"Discovery and Design of Human Antibodies to Broadly Neutralize Filoviruses"
11:55 am - 12:00 pmDiscussion
12:00 pm - 12:10 pmKaitlin Sawatzki (Boston University, USA)
"Non-Specific Activation of Autoreactive B Cells After Anthrax Vaccination Delays Protection"
12:10 pm - 12:15 pmDiscussion
12:15 pm - 12:25 pmNancy Sullivan (National Institutes of Health, USA)
"Protection of Macaques Against Ebola Virus Infection by a Single, Potently Neutralizing Antibody and Molecular Mechanism of Recognition"
12:25 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:30 pm - 9:30 pmUnique Therapeutic Vistas in Antibody Engineering: Bispecifics
This session aims to focus on novel and explorative preclinical and clinical applications of antibody modifications using novel bispecifics and multispecific technologies.
Discussion Leader: Paul Carter (Genentech, Inc., USA)
7:30 pm - 7:55 pmAntonin De Fougerolles (Ablynx NV, Belgium)
"Nanobodies as a Versatile and Clinically Validated Drug Platform"
7:55 pm - 8:05 pmDiscussion
8:05 pm - 8:30 pmTeemu Junttila (Genentech Inc., USA)
"Antitumor Efficacy of a Bispecific Antibody that Targets HER2 and Activates T Cells"
8:30 pm - 8:40 pmDiscussion
8:40 pm - 9:05 pmMichel Sadelain (Memorial Sloan Kettering Cancer Center, USA)
"CAR T Cell Engineering"
9:05 pm - 9:15 pmDiscussion
9:15 pm - 9:25 pmAran Labrijn (Genmab, The Netherlands)
"Bispecific Mouse Antibodies for Pre-Clinical Studies Generated by Controlled Fab-Arm Exchange"
9:25 pm - 9:30 pmDiscussion
Thursday
7:30 am - 8:30 amBreakfast
8:30 am - 9:00 amBusiness Meeting
Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
9:00 am - 12:30 pmCo-Opting Antibodies as a Delivery Vehicle
This session aims to focus on "Co-Opting antibodies as a Delivery Vehicle" (on novel and explorative preclinical and clinical applications of antibody modifications associated with antibody drug conjugates, cytokines or other approaches).
Discussion Leader: John Lambert (ImmunoGen, Inc., USA)
9:00 am - 9:25 amAmbily Abraham (Indian Institute of Science, India)
"Plant Virus Based Nanocarriers for Delivery of Therapeutic Antibodies"
9:25 am - 9:35 amDiscussion
9:35 am - 10:00 amChristian Klein (Roche Innovation Center Zurich, Switzerland)
"Antibody-Based Targeted Cancer Immunotherapy"
10:00 am - 10:10 amDiscussion
10:10 am - 10:40 amCoffee Break
10:40 am - 11:05 amXiuxia Sun (ImmunoGen, Inc., USA)
"Using Antibodies to Deliver Cytotoxic Agents into Cancer Cells"
11:05 am - 11:15 amDiscussion
11:15 am - 11:40 amK. Dane Wittrup (David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, USA)
"Anti-Tumor Antibodies as Immunotherapy - Beyond ADCC to Adaptive T Cell Responses"
11:40 am - 11:50 amDiscussion
11:50 am - 12:15 pmNimesh Gupta (National Institute of Immunology, India)
"Navigating Through The Materno-Fetal Interface to Establish Antigen-Specific Tolerance in Fetal Life"
12:15 pm - 12:25 pmDiscussion
12:25 pm - 12:30 pmGeneral Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:30 pm - 9:30 pmTherapeutic Challenges and Opportunities in the Application of Antibodies to Modifying Disease
This session aims to consider novel, ground-breaking opportunities for antibody therapies as in immune oncology or infectious diseases (e.g. HIV or Ebola).
Discussion Leader: Louis Weiner (Georgetown University, USA)
7:30 pm - 7:55 pmSergio Quezada (University College London, United Kingdom)
"Immune Check Point Inhibition"
7:55 pm - 8:05 pmDiscussion
8:05 pm - 8:30 pmPaul Parren (Genmab B.V., The Netherlands)
"Molecular Aspects of C1-Antibody Interactions"
8:30 pm - 8:40 pmDiscussion
8:40 pm - 8:50 pmNicolas Fischer (Novimmune, Switzerland)
"Selective Inhibition of the Immuno-Oncology Target CD47 Mediated by a Specific Antibody"
8:50 pm - 8:55 pmDiscussion
8:55 pm - 9:05 pmLlewelyn Lao (XOMA, USA)
"Antibody Engineering of XMetD to Produce XOMA129, a Rapidly Acting Insulin Receptor Modulator that Is a Potential Therapeutic Molecule for Treating Iatrogenic Hypoglycemia"
9:05 pm - 9:10 pmDiscussion
9:10 pm - 9:20 pmGeneral Discussion
9:20 pm - 9:30 pmClosing Remarks
Friday
7:30 am - 8:30 amBreakfast
9:00 amDeparture

Funding for this conference was made possible [in part] by 1R13AI122628-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
© 2017 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter